Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Post-Translational Modifications That Drive Prostate Cancer Progression (CROSBI ID 290823)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Samaržija, Ivana Post-Translational Modifications That Drive Prostate Cancer Progression // Biomolecules, 11 (2021), 2; 247, 44. doi: 10.3390/biom11020247

Podaci o odgovornosti

Samaržija, Ivana

engleski

Post-Translational Modifications That Drive Prostate Cancer Progression

While a protein primary structure is determined by genetic code, its specific functional form is mostly achieved in a dynamic interplay that includes actions of many enzymes involved in post- translational modifications. This versatile repertoire is widely used by cells to direct their response to external stimuli, regulate transcription and protein localization and to keep proteostasis. Herein, post-translational modifications with evident potency to drive prostate cancer are explored. A comprehensive list of proteome-wide and single protein post- translational modifications and their involvement in phenotypic outcomes is presented. Specifically, the data on phosphorylation, glycosylation, ubiquitination, SUMOylation, acetylation, and lipidation in prostate cancer and the enzymes involved are collected. This type of knowledge is especially valuable in cases when cancer cells do not differ in the expression or mutational status of a protein, but its differential activity is regulated on the level of post-translational modifications. Since their driving roles in prostate cancer, post-translational modifications are widely studied in attempts to advance prostate cancer treatment. Current strategies that exploit the potential of post-translational modifications in prostate cancer therapy are presented.

SUMOylation ; acetylation ; glycosylation ; lipidation ; phosphorylation ; post-translational modification ; prostate cancer ; ubiquitination

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

11 (2)

2021.

247

44

objavljeno

2218-273X

10.3390/biom11020247

Povezanost rada

Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

Poveznice
Indeksiranost